15025747

Source:http://linkedlifedata.com/resource/pubmed/id/15025747

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0017431, umls-concept:C0021469, umls-concept:C0025519, umls-concept:C0028978, umls-concept:C0085228, umls-concept:C1280500, umls-concept:C1332828
pubmed:issue	4
pubmed:dateCreated	2004-3-17
pubmed:abstractText	Omeprazole is mainly metabolized by the polymorphic cytochrome P450 (CYP) 2C19. The inhibitory effect of fluvoxamine, an inhibitor of CYP2C19 as well as CYP1A2, on the metabolism of omeprazole was compared between different genotypes for CYP2C19.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-10073749, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-10511917, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-10579481, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-11240980, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-11309556, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-11434512, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-11770010, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-11907488, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-11966672, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-12386647, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-12649369, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-1389950, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-1429977, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-1793525, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-1905641, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-1983325, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-7917780, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-7962687, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-7969038, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-7974626, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-8005185, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-8195181, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-8333005, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-8646822, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-8685072, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-8807660, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-8823236, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-9110356, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-9284848, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-9333103, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-9357389, http://linkedlifedata.com/resource/pubmed/commentcorrection/15025747-9867757
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7503323
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anti-Ulcer Agents, http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Hydroxylases, http://linkedlifedata.com/resource/pubmed/chemical/CYP2C19 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Fluvoxamine, http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases, http://linkedlifedata.com/resource/pubmed/chemical/Omeprazole, http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Uptake Inhibitors
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	0306-5251
pubmed:author	pubmed-author:InoueYoshimasaY, pubmed-author:KanekoSunaoS, pubmed-author:NakagamiTakuT, pubmed-author:TakahataTakenoriT, pubmed-author:TateishiTomonoriT, pubmed-author:Yasui-FurukoriNorioN, pubmed-author:YoshiyaGenG
pubmed:issnType	Print
pubmed:volume	57
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	487-94
pubmed:dateRevised	2009-11-18
pubmed:meshHeading	pubmed-meshheading:15025747-Adult, pubmed-meshheading:15025747-Anti-Ulcer Agents, pubmed-meshheading:15025747-Aryl Hydrocarbon Hydroxylases, pubmed-meshheading:15025747-Cross-Over Studies, pubmed-meshheading:15025747-Double-Blind Method, pubmed-meshheading:15025747-Drug Interactions, pubmed-meshheading:15025747-Female, pubmed-meshheading:15025747-Fluvoxamine, pubmed-meshheading:15025747-Heterozygote, pubmed-meshheading:15025747-Homozygote, pubmed-meshheading:15025747-Humans, pubmed-meshheading:15025747-Male, pubmed-meshheading:15025747-Mixed Function Oxygenases, pubmed-meshheading:15025747-Omeprazole, pubmed-meshheading:15025747-Serotonin Uptake Inhibitors
pubmed:year	2004
pubmed:articleTitle	Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
pubmed:affiliation	Department of Clinical Pharmacology, Hirosaki University, School of Medicine, Hirosaki, Japan. yasufuru@cc.hirosaki-u.ac.jp
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial